

TDMs No. 99028 - 06

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 04/07/2008

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

F1_M3

C Number: C99028

Lock Date: 09/20/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 2.0.0

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	7	4	2	8
Natural Death	6	6	6	14
Survivors				
Moribund Sacrifice		1		
Natural Death		1		1
Terminal Sacrifice	37	38	42	27
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(50)	(49)	(49)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)		
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma		2 (4%)	1 (2%)	
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Thyroid Gland	1 (2%)			
Hemangiosarcoma	1 (2%)	2 (4%)	4 (8%)	1 (2%)
Hemangiosarcoma, Metastatic, Skin				1 (2%)
Hemangiosarcoma, Metastatic, Spleen				1 (2%)
Hepatoblastoma	2 (4%)	2 (4%)	2 (4%)	2 (4%)
Hepatoblastoma, Multiple		1 (2%)		1 (2%)
Hepatocellular Adenoma	13 (26%)	14 (28%)	12 (24%)	15 (30%)
Hepatocellular Adenoma, Multiple	20 (40%)	26 (52%)	25 (50%)	11 (22%)
Hepatocellular Carcinoma	8 (16%)	14 (28%)	8 (16%)	7 (14%)
Hepatocellular Carcinoma, Multiple	6 (12%)	1 (2%)	2 (4%)	1 (2%)
Hepatocholangiocarcinoma		1 (2%)		
Ito Cell Tumor Benign	1 (2%)			
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Mesentery	(5)	(8)	(11)	(1)
Hemangioma	1 (20%)			
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (9%)	
Pancreas	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hemangioma		1 (2%)		
Squamous Cell Papilloma		1 (2%)		1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Tongue	(1)	(0)	(0)	(0)
Tooth	(5)	(5)	(4)	(1)
Odontoma	1 (20%)		2 (50%)	

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Thyroid Gland	1 (2%)			
Bilateral, Adenoma	1 (2%)			
Subcapsular, Adenoma	5 (10%)		3 (6%)	6 (12%)
Subcapsular, Carcinoma				1 (2%)
Adrenal Medulla	(49)	(50)	(50)	(50)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Parathyroid Gland	(47)	(33)	(45)	(46)
Pituitary Gland	(50)	(49)	(49)	(49)
Pars Distalis, Adenoma	1 (2%)			
Pars Intermedia, Adenoma	1 (2%)	1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Bilateral, Follicular Cell, Adenoma				1 (2%)
Follicular Cell, Adenoma		1 (2%)	3 (6%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Follicular Cell, Carcinoma	1 (2%)			
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	(50)
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(50)
Hemangioma	1 (2%)			
Seminal Vesicle	(50)	(50)	(50)	(50)
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma	2 (4%)	1 (2%)	2 (4%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Thyroid Gland	1 (2%)			
Hemangiosarcoma	1 (2%)	4 (8%)	1 (2%)	1 (2%)
Lymph Node	(2)	(1)	(2)	(1)
Mediastinal, Carcinoma, Metastatic, Thyroid Gland	1 (50%)			
Mediastinal, Osteosarcoma, Metastatic, Uncertain Primary Site			1 (50%)	
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Lymph Node, Mesenteric	(50)	(50)	(50)	(49)
Hemangiosarcoma			1 (2%)	
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma	3 (6%)	1 (2%)	3 (6%)	2 (4%)
Thymus	(49)	(49)	(47)	(49)
INTEGUMENTARY SYSTEM				
Mammary Gland	(1)	(0)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Carcinoma Skin	1 (100%) (50)	(50)	(50)	(50)
Basal Cell Carcinoma				1 (2%)
Keratoacanthoma		1 (2%)		
Site Of Application - Dermis, Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous Tissue, Hemangiosarcoma				1 (2%)
Subcutaneous Tissue, Schwannoma Malignant				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(0)	(0)	(0)	(1)
Hepatoblastoma, Metastatic, Liver				1 (100%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	10 (20%)	7 (14%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)	4 (8%)	1 (2%)	2 (4%)
Alveolar/Bronchiolar Carcinoma	4 (8%)	4 (8%)	4 (8%)	1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)			
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Carcinoma, Metastatic, Thyroid Gland	1 (2%)			
Hemangiosarcoma, Metastatic, Skin			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	6 (12%)	3 (6%)	4 (8%)
Osteosarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Mediastinum, Hemangioma		1 (2%)		
Mediastinum, Hemangiosarcoma				1 (2%)
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Sarcoma	1 (2%)			
Harderian Gland	(50)	(50)	(50)	(49)
Adenoma	10 (20%)	10 (20%)	8 (16%)	9 (18%)
Carcinoma	2 (4%)	1 (2%)		
Sarcoma	1 (2%)			
Bilateral, Adenoma				1 (2%)
Zymbal's Gland	(1)	(0)	(0)	(1)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Carcinoma, Metastatic, Thyroid Gland	1 (2%)			
Renal Tubule, Adenoma				1 (2%)
Urinary Bladder	(50)	(50)	(50)	(50)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)		1 (2%)	
Lymphoma Malignant		3 (6%)	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	150 MG/KG	300 MG/KG	600 MG/KG
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	48	46	45	37
Total Primary Neoplasms	97	110	94	76
Total Animals with Benign Neoplasms	41	42	39	34
Total Benign Neoplasms	63	71	63	53
Total Animals with Malignant Neoplasms	25	32	25	16
Total Malignant Neoplasms	34	39	31	23
Total Animals with Metastatic Neoplasms	5	8	5	7
Total Metastatic Neoplasms	11	8	10	7
Total Animals with Malignant Neoplasms Uncertain Primary Site			1	
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	11	5	7	11
Natural Death	8	7	6	2
Survivors				
Natural Death				1
Terminal Sacrifice	31	38	37	36
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Adenoma				1 (2%)
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)			
Hepatocellular Adenoma	11 (22%)	11 (22%)	9 (18%)	18 (36%)
Hepatocellular Adenoma, Multiple	11 (22%)	13 (26%)	6 (12%)	9 (18%)
Hepatocellular Carcinoma	1 (2%)	7 (14%)	8 (16%)	5 (10%)
Hepatocellular Carcinoma, Multiple	2 (4%)	1 (2%)		
Hepatocholangiocarcinoma			1 (2%)	
Mesentery	(16)	(13)	(11)	(10)
Fibrous Histiocytoma				2 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (9%)	
Sarcoma	1 (6%)			
Pancreas	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Hemangioma				1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Papilloma	1 (2%)	2 (4%)	4 (8%)	4 (8%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Tooth	(0)	(0)	(2)	(3)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Aorta, Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign		1 (2%)	1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma		1 (2%)		
Pituitary Gland	(49)	(50)	(50)	(50)
Pars Distalis, Adenoma	4 (8%)	11 (22%)	6 (12%)	4 (8%)
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		2 (4%)	1 (2%)	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Clitoral Gland	(50)	(50)	(49)	(50)
Hemangioma	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Ovary	(50)	(50)	(50)	(50)
Cystadenoma	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Hemangioma		1 (2%)		2 (4%)
Hemangiosarcoma		1 (2%)	1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Adenoma				2 (4%)
Carcinoma			1 (2%)	
Hemangioma		1 (2%)		1 (2%)
Hemangiosarcoma		1 (2%)	2 (4%)	
Polyp Stromal		2 (4%)		1 (2%)
Vagina	(0)	(0)	(1)	(0)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	1 (2%)	2 (4%)	
Lymph Node	(8)	(9)	(3)	(5)
Fibrosarcoma, Metastatic, Skin				1 (20%)
Pancreatic, Hepatocholangiocarcinoma, Metastatic, Liver			1 (33%)	
Lymph Node, Mandibular	(50)	(50)	(50)	(49)
Lymph Node, Mesenteric	(50)	(50)	(49)	(50)
Fibrous Histiocytoma, Metastatic, Mesentery				1 (2%)
Hemangiosarcoma		1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma	5 (10%)	2 (4%)	2 (4%)	1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Thymus	(50)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Fibrous Histiocytoma, Metastatic, Uncertain Primary Site				1 (2%)
Thymoma Malignant				1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(48)	(50)	(50)	(50)
Carcinoma	2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Skin	(50)	(50)	(50)	(50)
Site Of Application - Dermis, Hemangiosarcoma			1 (2%)	
Site Of Application - Dermis, Schwannoma Malignant	1 (2%)	1 (2%)		
Subcutaneous Tissue, Fibrosarcoma				2 (4%)
Subcutaneous Tissue, Fibrous Histiocytoma		1 (2%)	1 (2%)	2 (4%)
Subcutaneous Tissue, Hemangioma			1 (2%)	
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)			
Subcutaneous Tissue, Myxosarcoma			1 (2%)	
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)		1 (2%)	3 (6%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Osteosarcoma	1 (2%)			
Vertebra, Osteosarcoma	1 (2%)		1 (2%)	1 (2%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Spinal Cord	(2)	(0)	(1)	(0)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	3 (6%)	4 (8%)	6 (12%)
Alveolar/Bronchiolar Carcinoma	4 (8%)			2 (4%)
Carcinoma, Metastatic, Harderian Gland		1 (2%)		
Fibrous Histiocytoma, Metastatic, Mesentery				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver			2 (4%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Osteosarcoma, Metastatic, Bone	1 (2%)		1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Mediastinum, Hepatocolangiocarcinoma, Metastatic, Liver			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Pleura	(0)	(0)	(1)	(0)
Hepatocolangiocarcinoma, Metastatic, Liver			1 (100%)	
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	3 (6%)	6 (12%)	5 (10%)	5 (10%)
Carcinoma		3 (6%)		
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Urinary Bladder	(50)	(50)	(50)	(50)
Sarcoma	1 (2%)			
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	3 (6%)		4 (8%)	4 (8%)
Lymphoma Malignant	9 (18%)	13 (26%)	5 (10%)	10 (20%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

bis(2-Chloroethoxy)methane

Time Report Requested: 11:52:50

Route: SKIN APPLICATION

CAS Number: 111-91-1

First Dose M/F: 10/03/02 / 10/02/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	100 MG/KG	200 MG/KG	400 MG/KG
Tumor Summary for Females				
Total Animals with Primary Neoplasms (b)	44	43	38	44
Total Primary Neoplasms	71	88	70	89
Total Animals with Benign Neoplasms	27	35	30	37
Total Benign Neoplasms	34	55	39	55
Total Animals with Malignant Neoplasms	31	24	22	26
Total Malignant Neoplasms	37	33	31	34
Total Animals with Metastatic Neoplasms	1	1	5	6
Total Metastatic Neoplasms	1	1	14	8
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors